Effects of Octagam on Severe COVID-19: Retrospective Cohort Study of 93 Patients

93 critically ill COVID-19 patient records from a single-center retrospective study compare standard intensive care with and without adjunct Octagam treatment. The data includes baseline characteristics, survival outcomes, and inflammation marker changes, such as C-reactive protein levels. Author Figen Esen published the study as Open Access via paperswithcode.

Use Cases

• Compare survival outcomes based on treatment group and baseline APACHE II scores mentioned in the description
• Analyze changes in inflammation biomarkers like C-reactive protein relative to treatment protocols
• Model the effect of patient age and disease severity scores on clinical outcomes
• Conduct propensity score matching to address baseline imbalances in observational data

Strengths

• Includes 93 patient records with detailed clinical metrics like APACHE II and SOFA scores
• Reports specific survival statistics: 61% survival in treatment group vs 38% in control
• Contains quantified biomarker data, such as median change in C-reactive protein of -71.5 mg/L

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data is from a single-center retrospective study, which may limit generalizability

Provenance

Source

Figen Esen via paperswithcode

Collection Method

Retrospective analysis of patient data from a single center